In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Home News ODAC Votes Against Safety Profile of Secura Bio’s P13K Inhibitor back to News
minute read
In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.